Diagnosed prevalent cases of acromegaly in the 7 major markets (7MM*) combined is projected to grow from 43,220 cases in 2019 to 47,340 in 2029, at an annual growth rate (AGR) of 0.95 percent, reports GlobalData, a leading data and analytics company.
GlobalData's latest article, 'Acromegaly and Gigantism - Epidemiology Forecast to 2029', remarks that the principal drivers for the increasing trend in the diagnosed prevalent cases of acromegaly could be attributable to better awareness of the disease, as well as increased diagnostic techniques and changing population demographics in the respective markets.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, states: "The majority of the diagnosed prevalent cases of acromegaly in the 7MM are assumed to occur in men and women ages 40-69 years, which, in this study, is driven by a higher proportion of the population being in this age group. Acromegaly is more prevalent in women, who present at an older age with longer diagnostic delay. At presentation, women have a greater growth hormone level compared to men. Among acromegaly patients, the quality of life is more negatively affected by women both before and after treatment."